Profiles of measured and perceived bronchodilation. A placebo-controlled cross-over trial comparing formoterol and salmeterol in moderate persistent asthma

Pulmonary Pharmacology and Therapeutics

Volumn 17, Issue 4, 2004, Pages 205-212

  Schermer, T R J ^a   Hoff, W J ^b   Greefhorst, A P M ^c   Creemers, J P H M ^c,f   Sips, A P ^d   Westbroek, J ^e   Van Herwaarden, C L A ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b LAB Benelux BV Statistical Services   (Netherlands)

^c Hosp Streekziekenhuis Midden Twente   (Netherlands)

^d CENTRAL MILITARY HOSPITAL   (Netherlands)

^e De Tjongerschans Hospital   (Netherlands)

^f CATHARINA HOSPITAL   (Netherlands)

Author keywords

ANCOVA, analysis of covariance; ANOVA, analysis of variance; Asthma; ATS, American Thoracic Society; Bronchodilator agents; Cross; FEV1, forced expiratory volume in one second; Formoterol; Over studies; Perception; Salmeterol

Indexed keywords

FORMOTEROL; FORMOTEROL FUMARATE; SALMETEROL; SALMETEROL XINAFOATE;

ADULT; AGED; ARTICLE; ASTHMA; BRONCHODILATATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; CROSSOVER PROCEDURE; DISEASE ASSOCIATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; MALE; METERED DOSE INHALER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VISUAL ANALOG SCALE;

ADRENERGIC BETA-AGONISTS; ALBUTEROL; ASTHMA; BRONCHODILATOR AGENTS; CROSS-OVER STUDIES; DELAYED-ACTION PREPARATIONS; DOUBLE-BLIND METHOD; ETHANOLAMINES; FEMALE; HUMANS; MALE; METERED DOSE INHALERS; MIDDLE AGED; TIME FACTORS;

EID: 3042532658     PISSN: 10945539     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pupt.2004.03.003     Document Type: Article

References (24)

1. The British Guidelines on asthma management. 1995 review and position statement. Thorax. 52:1997;S1-S20
2. Bousquet J. Global initiative for asthma (GINA) and its objectives. Clin Exp Allergy. 30:(1):2000;2-5
3. Bone R.C. Another word of caution regarding a new long-acting bronchodilator. J Am Med Assoc. 273:1995;967-968
4. Taylor D.R., Sears M.R., Cockcroft D.W. The beta-agonist controversy. Med Clin North Am. 80:1996;719-748
5. Sears M.R. Long-acting beta-agonists, tachyphylaxis, and corticosteroids. Chest. 109:1996;862-864
6. Linden A., Rabe K.F., Lofdahl C.G. Pharmacological basis for duration of effect: formoterol and salmeterol versus short-acting beta 2-adrenoceptor agonists. Lung. 174:1996;1-22
7. Anderson G.P., Linden A., Rabe K.F. Why are long-acting beta-adrenoceptor agonists long-acting? Eur Respir J. 7:1994;569-578
8. van Noord J.A., Smeets J.J., Raaijmakers J.A.M. Salmeterol versus formoterol in patients with moderately severe asthma: onset and duration of action. Eur Respir J. 9:1996;1684-1688
9. Palmqvist M., Persson G., Lazer L., et al. Inhaled dry-powder formoterol and salmeterol in asthmatic patients: onset of action, duration of effect and potency. Eur Resp J. 10:1997;2484-2489
10. Grembiale R.D., Pelaia G., Naty S., et al. Comparison of the bronchodilating effects of inhaled formoterol, salmeterol and salbutamol in asthmatic patients. Pulm Pharmacol Ther. 15:2002;463-466
11. Rabe K.F., Jörres R., Nowak D. Comparison of the effects of salmeterol and formoterol on airway tone and responsiveness over 24 h in bronchial asthma. Am Rev Respir Dis. 146:1993;1156-1160
12. Campbell L.M., Anderson T.J., Parashchak M.R., Burke C.M., Watson S.A., Turbitt M.L. A comparison of the efficacy of long-acting beta 2-agonists: eformoterol via Turbohaler and salmeterol via pressurized metered dose inhaler or Accuhaler, in mild to moderate asthmatics. Respir Med. 93:1999;236-244
13. Condemi J.J. Comparison of the efficacy of formoterol and salmeterol in patients with reversible obstructive airway disease: a multicenter, randomized, open-label trial. Clin Ther. 23:2001;1529-1541
14. Palmqvist M., Ibsen T., Mellen A., Lötvall J. Comparison of the relative efficacy of formoterol and salmeterol in asthmatic patients. Am J Respir Crit Care Med. 160:1999;244-249
15. Ulrik C.S., Kok-Jensen A. Different bronchodilating effect of salmeterol and formoterol in an adult asthmatic. Eur Respir J. 7:1994;1003-1005
16. Noppen M., Vincken W. Bronchodilating effect of formoterol but not of salmeterol in two asthmatic patients. Respiration. 67:2000;112-113
17. Noseda A., Schmerber J., Prigogine T., et al. How do patients with either asthma or COPD perceive acute bronchodilation? Eur Respir J. 6:1993;636-644
18. Noseda A., Schmerber J., Prigogine T., et al. Perception of dyspnoe during acute changes in lung function in patients with either asthma or COPD. Respir Med. 89:1995;477-485
19. Lavietes M.H., Matta J., Tiersky L.A., Natelson B.H., Bielory L., Cherniack N.S. The perception of dyspnea in patients with mild asthma. Chest. 120:2001;409-415
20. American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. Am Rev Respir Dis. 136:1987;225-244
21. American Thoracic Society. Standardization of spirometry, 1994 update. Am J Respir Crit Care Med. 152:1995;1107-1136
22. Noseda A., Schmerber J., Prigogine T., et al. Perceived effect on shortness of breath of an acute inhalation of saline or terbutaline: variability and sensitivity of a visual analogue scale in patients with asthma or COPD. Eur Respir J. 5:1992;1043-1053
23. Senn S. Cross-over trials in clinical research. 1st. 1993;64
24. Tan S., Hall I.P., Dewar J., et al. Association between beta 2-adrenoceptor polymorphism and susceptibility to bronchodilator desensitisation in moderately severe stable asthmatics. Lancet. 350:1997;995-999